id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0611-0091,FDA,FDA-2011-D-0611,Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act; Guidance for Industry; Draft Guidance,Other,Guidance,2023-09-15T00:00:00Z,2023,9,2023-09-15T00:00:00Z,,2025-05-06T01:33:49Z,,1,0,0900006485fb1ea4